Dr. Curtis has received consultant fees and/or honoraria (less than $10,000 each) from Merck and Lilly and (more than $10,000 each) from Amgen and Roche, and has received research support from Amgen, Merck, Lilly, and Roche.
Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population
Version of Record online: 26 JUN 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 7, pages 1054–1060, July 2012
How to Cite
Curtis, J. R., Yun, H., Matthews, R., Saag, K. G. and Delzell, E. (2012), Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population. Arthritis Care Res, 64: 1054–1060. doi: 10.1002/acr.21638
- Issue online: 26 JUN 2012
- Version of Record online: 26 JUN 2012
- Accepted manuscript online: 10 FEB 2012 04:36PM EST
- Manuscript Accepted: 3 FEB 2012
- Manuscript Received: 29 AUG 2011
- NIH. Grant Numbers: AR-053351, AR-052361
- Agency for Healthcare Research and Quality. Grant Number: R01-HS018517
- Agency for Healthcare Research and Quality. Grant Number: U18-HS016956
- 4Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122 Suppl :S3–13., , , , , .
- 9Office of the Surgeon General. Bone health and osteoporosis: a report of the Surgeon General. Rockville (MD): US Department of Health and Human Services; 2004.
- 23C-B4–03: promoting adherence to improve effectiveness of cardiovascular disease therapies (PATIENT): implementing a medication adherence intervention using health information technology. Clin Med Res 2011; 9: 152., , , , , , et al.
- 24Use of health information technology to improve medication adherence. Am J Manag Care 2011; 17: SP79–87., , , , , , et al.